Georgiamune
Georgiamune is a clinical-stage biotech company developing first-in-class immunotherapies for cancer and autoimmune diseases using an 'immune-reset' approach.
Secondary Market Price
How Georgiamune Measures Up
To help you manage your Georgiamune equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Georgiamune's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Georgiamune Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Georgiamune's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Georgiamune Inc. is a private, clinical-stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to treat cancer and autoimmune diseases. Founded in 2017 by Dr. Samir Khleif, the company develops therapies based on scientific discoveries in immune signaling and balance. Its current work includes advancing three first-in-class immunotherapies into clinical trials and developing an immune-reset pill for autoimmune diseases designed to bypass the bloodstream and target the root cause of the illness without major side effects.
The company plans to continue advancing its pipeline of immunotherapies with the goal of creating safer, more targeted treatments. Georgiamune has received recent industry recognition, having been named a Fierce 15 company for 2025 by Fierce Biotech and winning the 2025 Clinical Immunology Solution of the Year award from BioTech Breakthrough. In 2025, CEO Samir Khleif was also selected for OncoDaily's list of the 100 Most Influential CEOs in Oncology. Additionally, the company's scientific advisor, Dr. Fred Ramsdell, was awarded The Nobel Prize in Physiology or Medicine for his contributions to the discovery of regulatory T cells.
- General Catalyst
- Parker Institute for Cancer Immunotherapy
- Mubadala Capital
- Alexandria Venture Investments
- Catalio Capital Management
- CJNV BioVenture
- Verition Fund Management
- Co-Founder, Samir N. Khleif
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Georgiamune worth joining?
Deciding whether to join Georgiamune depends on your personal career goals and your assessment of the company's long-term potential. Tools like Prospect can help you analyze the financial upside of your equity offer by providing data-driven projections on its future value.
What should I do with my Georgiamune stock?
Managing private company stock requires careful planning around when to exercise options and how to minimize your tax burden. Platforms like Prospect offer customized strategies to help you make informed decisions and optimize the post-tax value of your Georgiamune equity.
Can you sell Georgiamune stock?
Selling stock in a private company like Georgiamune is typically possible during specific liquidity events, such as a tender offer or a secondary sale. Tools like Prospect can help you navigate these opportunities and determine the most tax-optimal shares to sell.
How can I find the value of my Georgiamune stock?
Since Georgiamune is a private company, its stock value isn't publicly available and can be difficult to determine. You can use platforms like Prospect, which leverage proprietary predictive models to forecast your equity's potential future value based on various data points.
What is Georgiamune's equity worth?
The precise worth of Georgiamune's private equity is not public information and depends on factors like company valuation and your specific grant details. To understand its potential value, you can use services like Prospect to model different scenarios and project your potential post-tax earnings.
What is Georgiamune's stock ticker symbol?
As a private, pre-IPO company, Georgiamune does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they become publicly traded on a stock exchange like the NYSE or NASDAQ.
Can I buy or sell Georgiamune stock?
As an employee, you can "buy" stock by exercising your vested options, and you may be able to sell shares during company-approved liquidity events like tender offers. Platforms such as Prospect provide tools and strategies to help you navigate both exercising and selling decisions optimally.
What is the criteria to buy or invest in Georgiamune stock?
For most individuals, the primary way to acquire stock in a private company like Georgiamune is by being an employee and receiving equity compensation. Direct investment is generally restricted to accredited investors participating in official financing rounds.
